Search results
Top Stock Reports for Broadcom, Merck & Airbnb
Zacks via Yahoo Finance· 2 days agoToday's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Merck & Co., Inc. (MRK) and Airbnb, Inc. (ABNB).
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Zacks via Yahoo Finance· 3 days agoMerck MRK announced that it is discontinuing a cohort of the phase III study evaluating a...
Is Johnson & Johnson Stock A Better Pick Over Merck?
Forbes· 3 days agoAlthough Merck trades at a higher valuation of 5.5x trailing revenues, compared to 4.2x for J&J, we think that this valuation gap will likely narrow over...
3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance
Zacks via Yahoo Finance· 21 hours agoHere we discuss three drugmakers, Eli Lilly and Company (LLY), Novo Nordisk (NVO) and Merck (MRK),...
Merck Expands Access to High-Quality Maternal Care for More
3BL CSRwire· 4 days agoMerck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Merck for Mothers, the company’s global maternal health initiative ...
Merck stops testing combo drug for skin cancer as more patients discontinue
Reuters via AOL· 4 days agoThis is the latest setback for the experimental drug, vibostolimab, and the related promising new...
Profit down at German pharmaceutical firm Merck in first quarter
dpa international via Yahoo Finance· 2 days agoProfit after income tax at German pharmaceutical firm Merck declined 12.5% to €699 million ($756.9...
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma...
Benzinga via Yahoo Finance· 4 days agoMonday, Merck & Co Inc (NYSE:MRK) announced the discontinuation of the vibostolimab and...
The Zacks Analyst Blog Highlights Broadcom, Merck, Airbnb, ONEOK and PG&E
Zacks· 1 day agoStocks recently featured in the blog include: Broadcom Inc. (AVGO Quick QuoteAVGO - Free Report) , Merck & Co., Inc. (MRK Quick QuoteMRK - Free Report) , Airbnb, Inc. (ABNB ...
Merck halts phase 3 TIGIT trial after immune-mediated adverse events prompt discontinuations
FierceBiotech· 4 days agoMerck & Co. has bailed early on a phase 3 test of the anti-TIGIT antibody vibostolimab after a high...